Cargando…

Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS)

BACKGROUND: Multiple myeloma is an incurable cancer with a rising incidence globally. Less toxic treatments are increasingly available, so patients are living longer and treatment decisions are increasingly guided by QOL concerns. There is no QOL assessment tool designed specifically for use in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osborne, Thomas R, Ramsenthaler, Christina, Schey, Stephen A, Siegert, Richard J, Edmonds, Polly M, Higginson, Irene J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404617/ https://www.ncbi.nlm.nih.gov/pubmed/25884627 http://dx.doi.org/10.1186/s12885-015-1261-6

Ejemplares similares

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods
por: Ramsenthaler, Christina, et al.
Publicado: (2017)

Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care
por: Gerlach, Christina, et al.
Publicado: (2020)

The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma
por: Davies, Joanna M., et al.
Publicado: (2017)

The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
por: Ramsenthaler, Christina, et al.
Publicado: (2016)

Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life
por: Osborne, Thomas R, et al.
Publicado: (2014)

Survival from multiple myeloma in England and Wales up to 2001
por: Schey, S
Publicado: (2008)

Reliability and Validity of the Greek QLQ-C30 and QLQ-MY20 for Measuring Quality of Life in Patients with Multiple Myeloma
por: Kontodimopoulos, Nick, et al.
Publicado: (2012)

Development of a Patient-Reported Palliative Care-Specific Health Classification System: The POS-E
por: Dzingina, Mendwas, et al.
Publicado: (2017)

Risk of relapse of multiple myeloma following kidney transplantation
por: Shah, Sapna, et al.
Publicado: (2019)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Cross-cultural validity of the Death Reflection Scale during the COVID-19 pandemic
por: Ramsenthaler, Christina, et al.
Publicado: (2022)

A brief, patient- and proxy-reported outcome measure in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS)
por: Murtagh, Fliss EM, et al.
Publicado: (2019)

Discovering the hidden benefits of cognitive interviewing in two languages: The first phase of a validation study of the Integrated Palliative care Outcome Scale
por: Schildmann, Eva K, et al.
Publicado: (2015)

Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma
por: Rata, Mihaela, et al.
Publicado: (2022)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
por: Markus, Efrat, et al.
Publicado: (2020)

Individual quality of life in patients with multiple myeloma
por: Dürner, Julia, et al.
Publicado: (2013)

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
por: Proskorovsky, Irina, et al.
Publicado: (2014)

Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients
por: Sully, Kate, et al.
Publicado: (2019)

Assessing the feasibility, acceptability and potential effectiveness of Dignity Therapy for people with advanced cancer referred to a hospital-based palliative care team: Study protocol
por: Hall, Sue, et al.
Publicado: (2009)

Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients
por: Barrett, Aisling, et al.
Publicado: (2021)

Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma
por: Silveira, Lívia Pena, et al.
Publicado: (2021)

Hypophosphatemia in Patients With Multiple Myeloma
por: Cancarevic, Ivan, et al.
Publicado: (2023)

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
por: Engelhardt, Monika, et al.
Publicado: (2017)

Multiple Myeloma
por: Parker, D., et al.
Publicado: (1979)

The Myeloma Globulins
por: McConnell, R. J., et al.
Publicado: (1958)

Timing the initiation of multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2020)

Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option
por: Lazana, I., et al.
Publicado: (2022)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma
por: Liu, Xiao-Ping, et al.
Publicado: (2019)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis
por: Li, Feng, et al.
Publicado: (2017)

Recent Advances in the Treatment of Patients with Multiple Myeloma
por: Legarda, Mario A., et al.
Publicado: (2020)

Randomised controlled trial of a new palliative care service: Compliance, recruitment and completeness of follow-up
por: Higginson, Irene J, et al.
Publicado: (2008)

Pseudohyperphosphatemia in a Patient with Multiple Myeloma
por: Lee, Yonggu, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_est19tds1dp9kcqclmlh5kgbk7